A Subcutaneously Administered Investigational RNAi Therapeutic (ALN-CC5) Targeting Complement C5 for Treatment of PNH and Complement-Mediated Diseases: Interim Phase 1 Study Results

被引：10

作者：

Hill, Anita ^{[1
,2
]}

Taubel, Jorg ^{[3
]}

Bush, Jim ^{[4
]}

Borodovsky, Anna ^{[5
]}

Kawahata, Noriyuki ^{[5
]}

Mclean, Helen ^{[5
]}

Powell, Christine ^{[5
]}

Chaturvedi, Prasoon ^{[5
]}

Warner, Garvin ^{[5
]}

Garg, Pushkal ^{[5
]}

Sorensen, Benny ^{[5
]}

机构：

[1] St James Inst Oncol, Leeds, W Yorkshire, England

[2] Leeds Teaching Hosp, Leeds, W Yorkshire, England

[3] St Georges Univ London, London, England

[4] Covance Clin Res Unit, Leeds, W Yorkshire, England

[5] Ainyiam Pharmaceut, Cambridge, MA USA

来源：

关键词：

D O I：

10.1182/blood.V126.23.2413.2413

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：3